News & Insights

Two numbers, one decision: making climate-health valuation usable across sectors

An OHE insight, ahead of OHE’s participation in the Health Diplomacy House panel at the 79th World Health Assembly (Geneva, 21 May 2026).

Sustainability

Valuing patient and carer time in HTA: equity and opportunity cost 

We address two criticisms of valuing patient and carer time in HTA: that it would displace health outcomes by misallocating a fixed budget, and that it would introduce inequities based on individual productivity or income. We argue that patient and carer time are vital inputs to healthcare, and that ignoring them reduces rather than improves both efficiency and fairness.

Is the revised Congressional Budget Office model of new drug development fit for purpose?

As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical revenues might affect R&D incentives, but the Congressional Budget Office’s (CBO) revised simulation model of new drug development remains too simplified and insufficiently validated to guide real-world decisions.

Around the World in HTA: Japan – An algorithmic approach to containing costs

Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.